A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus

OBJECTIVE: Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatham, W, Chadha, A, Fettiplace, J, Kleoudis, C, Bass, D, Roth, D, Gordon, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673008/
https://www.ncbi.nlm.nih.gov/pubmed/28467293
http://dx.doi.org/10.1177/0961203317703495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673008/
https://www.ncbi.nlm.nih.gov/pubmed/28467293
http://dx.doi.org/10.1177/0961203317703495

Ejemplares similares